115 related articles for article (PubMed ID: 37196147)
1. Correlation between recurrence-free survival and overall survival after upfront surgery for resected colorectal liver metastases.
Kataoka K; Takahashi K; Takeuchi J; Ito K; Beppu N; Ceelen W; Kanemitsu Y; Ajioka Y; Endo I; Hasegawa K; Takahashi K; Ikeda M
Br J Surg; 2023 Jun; 110(7):864-869. PubMed ID: 37196147
[TBL] [Abstract][Full Text] [Related]
2. Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases.
Satake H; Hashida H; Tanioka H; Miyake Y; Yoshioka S; Watanabe T; Matsuura M; Kyogoku T; Inukai M; Kotake T; Okita Y; Matsumoto T; Yasui H; Kotaka M; Kato T; Kaihara S; Tsuji A
Oncologist; 2021 Jul; 26(7):e1125-e1132. PubMed ID: 33977607
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis.
Kim HR; Min BS; Kim JS; Shin SJ; Ahn JB; Rho JK; Kim NK; Rha SY
Oncology; 2011; 81(3-4):175-83. PubMed ID: 22057187
[TBL] [Abstract][Full Text] [Related]
4. Multicentre study of perioperative
Allard MA; Nishioka Y; Beghdadi N; Imai K; Gelli M; Yamashita S; Kitano Y; Kokudo T; Yamashita YI; Sa Cunha A; Vibert E; Elias D; Cherqui D; Goere D; Adam R; Baba H; Hasegawa K
BJS Open; 2019 Oct; 3(5):678-686. PubMed ID: 31592094
[TBL] [Abstract][Full Text] [Related]
5. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
Snoeren N; Voest EE; Bergman AM; Dalesio O; Verheul HM; Tollenaar RA; van der Sijp JR; Schouten SB; Rinkes IH; van Hillegersberg R
BMC Cancer; 2010 Oct; 10():545. PubMed ID: 20937118
[TBL] [Abstract][Full Text] [Related]
6. Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases.
Wang Y; Yuan YF; Lin HC; Li BK; Wang FH; Wang ZQ; Ding PR; Chen G; Wu XJ; Lu ZH; Pan ZZ; Wan DS; Sun P; Yan SM; Xu RH; Li YH
Chin J Cancer; 2017 Oct; 36(1):78. PubMed ID: 28969708
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II study of 5-fluorouracil hepatic arterial infusion with or without antineoplastons as an adjuvant therapy after hepatectomy for liver metastases from colorectal cancer.
Ogata Y; Matono K; Tsuda H; Ushijima M; Uchida S; Akagi Y; Shirouzu K
PLoS One; 2015; 10(3):e0120064. PubMed ID: 25790229
[TBL] [Abstract][Full Text] [Related]
8. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
[TBL] [Abstract][Full Text] [Related]
9. Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis.
Ecker BL; Lee J; Saadat LV; Aparicio T; Buisman FE; Balachandran VP; Drebin JA; Hasegawa K; Jarnagin WR; Kemeny NE; Kingham TP; Groot Koerkamp B; Kokudo N; Matsuyama Y; Portier G; Saltz LB; Soares KC; Wei AC; Gonen M; D'Angelica MI
Lancet Oncol; 2022 Oct; 23(10):1332-1342. PubMed ID: 36058227
[TBL] [Abstract][Full Text] [Related]
10. Significance of postoperative adjuvant chemotherapy with an oxaliplatin-based regimen after simultaneous curative resection for colorectal cancer and synchronous colorectal liver metastasis: a propensity score matching analysis.
Sugimoto K; Sakamoto K; Ii Y; Amemiya K; Sugo H; Ito T; Munakata S; Takahashi M; Kojima Y; Tomiki Y; Sato K; Saiura A; Kawasaki S
BMC Surg; 2021 Apr; 21(1):188. PubMed ID: 33836701
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
[TBL] [Abstract][Full Text] [Related]
12. Survival Benefit of and Indications for Adjuvant Chemotherapy for Resected Colorectal Liver Metastases-a Japanese Nationwide Survey.
Kobayashi S; Beppu T; Honda G; Yamamoto M; Takahashi K; Endo I; Hasegawa K; Kotake K; Itabashi M; Hashiguchi Y; Kotera Y; Sakamoto K; Yamaguchi T; Morita S; Tabuchi K; Miyazaki M; Sugihara K
J Gastrointest Surg; 2020 Jun; 24(6):1244-1260. PubMed ID: 31197683
[TBL] [Abstract][Full Text] [Related]
13. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Nordlinger B; Sorbye H; Glimelius B; Poston GJ; Schlag PM; Rougier P; Bechstein WO; Primrose JN; Walpole ET; Finch-Jones M; Jaeck D; Mirza D; Parks RW; Mauer M; Tanis E; Van Cutsem E; Scheithauer W; Gruenberger T; ; ; ; ;
Lancet Oncol; 2013 Nov; 14(12):1208-15. PubMed ID: 24120480
[TBL] [Abstract][Full Text] [Related]
14. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer.
House MG; Kemeny NE; Gönen M; Fong Y; Allen PJ; Paty PB; DeMatteo RP; Blumgart LH; Jarnagin WR; D'Angelica MI
Ann Surg; 2011 Dec; 254(6):851-6. PubMed ID: 21975318
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.
Andreou A; Kopetz S; Maru DM; Chen SS; Zimmitti G; Brouquet A; Shindoh J; Curley SA; Garrett C; Overman MJ; Aloia TA; Vauthey JN
Ann Surg; 2012 Oct; 256(4):642-50. PubMed ID: 22968062
[TBL] [Abstract][Full Text] [Related]
16. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
Portier G; Elias D; Bouche O; Rougier P; Bosset JF; Saric J; Belghiti J; Piedbois P; Guimbaud R; Nordlinger B; Bugat R; Lazorthes F; Bedenne L
J Clin Oncol; 2006 Nov; 24(31):4976-82. PubMed ID: 17075115
[TBL] [Abstract][Full Text] [Related]
17. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB
Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681
[TBL] [Abstract][Full Text] [Related]
19. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
Lévi FA; Boige V; Hebbar M; Smith D; Lepère C; Focan C; Karaboué A; Guimbaud R; Carvalho C; Tumolo S; Innominato P; Ajavon Y; Truant S; Castaing D; De Baere T; Kunstlinger F; Bouchahda M; Afshar M; Rougier P; Adam R; Ducreux M;
Ann Oncol; 2016 Feb; 27(2):267-74. PubMed ID: 26578731
[TBL] [Abstract][Full Text] [Related]
20. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.
Kemeny NE; Chou JF; Capanu M; Gewirtz AN; Cercek A; Kingham TP; Jarnagin WR; Fong YC; DeMatteo RP; Allen PJ; Shia J; Ang C; Vakiani E; D'Angelica MI
Cancer; 2014 Dec; 120(24):3965-71. PubMed ID: 25155157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
